Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company, has entered into an agreement to transfer its portfolio of branded prescription products to Apotex, a Canadian-based pharmaceutical company, in a transaction valued at $100 million in cash.
The deal will integrate Cumberland's U.S. commercial business into Apotex, creating a broader platform for distributing specialty medicines across the country. The transaction remains subject to authorization and approval by Cumberland's shareholders.
Cumberland will retain its development-stage pipeline, including Ifetroban, a thromboxane antagonist being evaluated across multiple Phase II programs. The company recently reported breakthrough results in a study of Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy (DMD), and additional trials are underway in systemic sclerosis and idiopathic pulmonary fibrosis (IPF).
CEO A.J. Kazimi said the transaction allows Cumberland to sharpen its focus on advancing these pipeline candidates, while Apotex gains additional commercial scale to support patient care. Apotex CEO Jeff Watson noted that integrating Cumberland's brands will strengthen the company's ability to deliver high-quality medicines across the U.S.
Cumberland will continue to hold its majority ownership in Cumberland Emerging Technologies, which supports early-stage drug development partnerships.
CPIX has traded between $1.85 and $6.27 over the past year. The stock is currently trading at $4.53, up 48.20%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.